Equity
€5,955 from €145,713 in 2022
Equity fell by 96% in 3 years.
Dermicea
Lifetime
5 annual accounts with figures on one time axispeak €102,708 (2021)
€29,747▼ 66.2%
peak €81,387 (2021)
€11,069▼ 81.7%
peak €145,713 (2022)
€5,955▼ 93.7%
€126,518▲ 64.3%
Board1 name since 2021
1 director
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Gross margin from €88,129 to €29,747Result from €60,428 to €11,069Dividend €100,000Equity from €94,885 to €5,955Debts from €77,016 to €126,518
Key points
from the 2025 annual accountsTurnover
≈ €92,000 estimated
The micro format states no turnover.
Debts
€126,518 96% of the balance sheet
After one year 5%Within one year 95%
Of this, €119,632 falls due within a year.
Liquidity
0.92 was 2.34 in 2024
Short-term debts rose from €59,941 to €119,632.
Filings
5 annual accounts 3 late
The 2022 accounts came latest: 31 days after the end of the period.
Position in the sector
4.5%
Lower solvency than 90% of companies in human health. Sector median 63.0% · 21,311 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,153 companies had the same profile as Dermicea has now. Each dot stands for 6 companies, two years later.
96.0%
were still trading
2.2%
stopped another way
1.7%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,153 companies, not a prediction for Dermicea. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0765875475
Registered office moved from Antwerp to Mortsel
New registered office: Pastoor Deensstraat 19, 2640 Mortsel · Previous registered office: Kanunnik Peetersstraat 45 bus 1, 2600 Antwerpen · General meeting of 13-11-2023 · Gazette deed
Incorporation
Founding capital of €5,000, 50 shares · Founder: · Appointment: (statutory director) · published on 01-04-2021 · Gazette deed
First establishment
Pastoor Deensstraat 19, Mortsel
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| Dermicea Mortsel | €132,473 | €29,747 | 4.5% | - |
| Dr. Beeckmans Nele - Fysische Geneeskunde, Revalidatie en Sportgeneeskunde Hoegaarden | €141,132 | €30,008 | 99.5% | - |
| DERMATODUMON Wezembeek-Oppem | €129,922 | €26,431 | 45.2% | - |
| DR. M.R. TROMP Sint-Gillis-Waas | €119,689 | €32,084 | 48.5% | - |
| REGENIX Ixelles | €129,705 | €33,442 | 47.9% | - |
| BENIUGA ANAPATH CONSULTING Pont-à-Celles | €153,053 | €33,336 | 95.1% | - |
| Reumapraktijk Dr. Moris M. Tremelo | €107,283 | €25,811 | 16.7% | - |
These companies have the same main activity as Dermicea: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €107,000 and €153,000, founded between 2020 and 2022.
Official details
Source: KBO- Status
- Active since 30-03-2021Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.316.398.0082640 Mortsel, since 30-03-2021
- Financial year end
- 31 December
- Peppol
- Reachable since 06-03-2026
Annual accounts 2025
- €132,473▼ 22.9%
- Filing
- Filed on 30-06-2026, 31 days before the end of the filing period
Insights on Dermicea
Dermicea files the micro format. That format states no turnover. The gross margin fell from €102,708 in 2021 to €29,747 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about Dermicea
- What is the company number of Dermicea?
- The company number of Dermicea is 0765.875.475. The VAT number is the same number with BE in front: BE 0765.875.475.
- Where is Dermicea based?
- The registered office is at Pastoor Deensstraat 19, 2640 Mortsel.Company details
- What does Dermicea do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of Dermicea?
- Dermicea is a private limited company (BV).
- When was Dermicea founded?
- Dermicea was founded on 30-03-2021.
- Is Dermicea still active?
- Yes, Dermicea is an active enterprise in the KBO register.
- What is the turnover of Dermicea?
- The turnover in financial year 2025 is ≈ €92,000. This figure is estimated from the gross margin of €29,747 and 47 comparable companies (NACE 86). It probably lies between €66,000 and €130,000.Financials
- Is Dermicea profitable?
- In financial year 2025, Dermicea made a profit of €11,069.
- Where can I find the annual accounts of Dermicea?
- Dermicea filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Dermicea due?
- Dermicea must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.